Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2025-08-29 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司章程
Governance Information Classification · 100% confidence The document is a detailed company charter or articles of association (章程) for Changchun BCHT Biotechnology Co., Ltd. It includes comprehensive sections on company general provisions, business scope, share issuance, shareholders and shareholder meetings, board of directors, senior management, financial accounting systems, profit distribution, auditing, notices and announcements, mergers, amendments to the charter, and other corporate governance matters. It references relevant laws such as the Company Law and Securities Law of China, and regulatory bodies like the China Securities Regulatory Commission (CSRC). The document is lengthy (15,000 characters) and contains detailed governance rules and procedures rather than financial statements or earnings data. It is not an announcement or a brief summary but a full governance document. Therefore, it fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-08-29 Chinese
长春百克生物科技股份公司信息披露暂缓与豁免事务管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy and procedural manual titled 'Information Disclosure Delay and Exemption Management System' for Changchun Baike Biotechnology Co., Ltd. It outlines rules, responsibilities, and procedures related to delaying or exempting disclosure of certain information, including definitions, approval processes, confidentiality commitments, and record-keeping. It references relevant laws and stock exchange rules but does not contain financial statements, earnings data, or any form of financial report. It is a governance-related document focused on disclosure management and compliance procedures rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR). The document length (6004 characters) and content confirm it is not a brief announcement or a certification but a substantive governance policy document.
2025-08-29 Chinese
长春百克生物科技股份公司股权激励管理办法
Governance Information Classification · 95% confidence The document is titled as a "股权激励管理办法" which translates to "Equity Incentive Management Measures". It is a detailed internal policy document outlining the rules, procedures, and governance related to the company's equity incentive plans for directors, senior management, and other employees. It includes legal references, eligibility criteria, types of equity incentives (restricted stock, stock options), implementation procedures, disclosure requirements, and supervisory management. There is no indication that this is a financial report, earnings release, or regulatory filing announcement. It is not a report of voting results, nor a management change announcement. It is a governance-related document detailing internal rules and practices regarding equity incentives. Therefore, the most appropriate classification is Governance Information (CGR). The document length and detail support this classification with high confidence.
2025-08-29 Chinese
长春百克生物科技股份公司募集资金管理制度
Regulatory Filings Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System'. It details the rules and procedures for the management, use, supervision, and reporting of funds raised by the company through stock issuance or other equity securities. The content includes regulatory references, internal controls, usage restrictions, reporting requirements, and responsibilities related to the raised funds. It is a detailed policy or management system document rather than a financial report, earnings release, or announcement. It does not contain financial statements or results, nor is it a brief announcement or presentation. It is a regulatory compliance and internal governance document related to capital management. Therefore, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory and compliance documents that do not fit other specific categories.
2025-08-29 Chinese
长春百克生物科技股份公司关于取消监事会、修订《公司章程》及新增、修订公司部分治理制度的公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding corporate governance changes, specifically about the cancellation of the supervisory board, amendments to the company's articles of association, and updates to governance systems. It includes detailed legal references, specific articles of the company charter, and governance rules. There is no indication of financial statements, audit results, earnings data, or investor presentations. The content focuses on governance structure and regulatory compliance related to company bylaws and board structure. This fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-08-29 Chinese
长春百克生物科技股份公司2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "长春百克生物科技股份公司2025 年半年度报告" which translates to "Changchun BCHT Biotechnology Co., Ltd. 2025 Semi-Annual Report." It covers the period from January 1, 2025 to June 30, 2025, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data such as revenue, net profit, cash flow, and earnings per share, as well as management discussion and analysis, risk factors, company overview, product information, R&D progress, marketing, production quality, and internal controls. The document is about 15,000 characters long, which is substantial and contains actual financial statements and substantive analysis. It is explicitly stated as a "半年度报告" (semi-annual report), which corresponds to an Interim / Quarterly Report. Therefore, the document is best classified as an Interim / Quarterly Report (IR). H1 2025
2025-08-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.